Abstract

Treating Inner Ear Disorders with Intratympanic Drug Administration

Author(s): McElhiney Linda F

Issue: Jul/Aug 2011 - Volume 15, Number 4

Page(s): 302-307

Download in electronic PDF format for $75

Abstract

Inner ear diseases are often treated in outpatient clinic settings that do not have United States Pharmacopeia Chapter <797>-compliant facilities to prepare the medications used for intratympanic administration. Compounding pharmacists can provide a valuable service to otolaryngologists by preparing these compounds in a sterile environment and hopefully reduce the chance of infection for these patients. This article focuses on the use and compounding of intratympanic dexamethasone to treat sudden sensorineural hearing loss and the use of intratympanic buffered gentamicin to treat the incapacitating vertigo in Ménière’s disease.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jul/Aug 2011 Pg. 302-307	Treating Inner Ear Disorders with Intratympanic Drug Administration Author(s): McElhiney Linda F
Jan/Feb 2004 Pg. 46-48	Basics of Compounding for Disorders of the External Ear Author(s): Allen Loyd V Jr
May/Jun 2003 Pg. 170-174	Five Compounds for Treating Diabetes-Related Conditions Author(s): Meece Jerry
Sep/Oct 2009 Pg. 386-389	Skin Disorders in Horses; Case Report: Tripelennamine in the Treatment of Skin Disorders in Horses Author(s): Williams LaVonn A, Fokken Dawn
Mar/Apr 2018 Pg. 92	PreScription: Drug Quality and Security Act Implementation Subcommittee Hearing Author(s): Allen Loyd V Jr
May/Jun 2003 Pg. 188-191	Treating Canine Hepatic Disease Author(s): Davidson Gigi S
May/Jun 2010 Pg. 182-192	Compounded Analgesic Therapy for Disorders of Movement: Arthritis, Neuropathic Pain, and Postpolio Syndrome Author(s): Brown Scott, Erickson Brian, Muller George, Bryant-Snure Susan J, Mestayer Richard F III
Jan/Feb 2008 Pg. 8-14	Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration Author(s): Dib Jean G, Abdulmohsin Saud
Jul/Aug 2003 Pg. 288-291	Basics of Compounding for Raynaud's Disease Author(s): Glasnapp Andrew
Sep/Oct 2017 Pg. 356	PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Author(s): Allen Loyd V Jr
Mar/Apr 1997 Pg. 87-89	Attention Deficit Hyperactivity Disorder Author(s): Allen Loyd V Jr
Jul/Aug 1998 Pg. 277	Swim Ear Drops ( "In Your Ear" ) Author(s): Nelson James L
Mar/Apr 2010 Pg. 171-173	Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders Author(s): Ploesser Jennifer, Weinstock Leonard B, Thomas Erin
Jan/Feb 2018 Pg. 57	Sodium Citrate 9% Nasal Spray for Olfactory Disorders Author(s): Allen Loyd V Jr
Jan/Feb 2020 Pg. 30-36	Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs Author(s): Dillon L R
Jul/Aug 2016 Pg. 351 View Sample	Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Author(s): Allen Loyd V Jr
Jan/Feb 2001 Pg. 21-22	Methylphenidate in the Treatment of Attention Deficit Disorders Author(s): Tenreiro Kim
Jul/Aug 2005 Pg. 275-278	Compounding for Endocrine Disorders in Adult Patients Author(s): Grajeda Betty Jo, Vail Jane
Jul/Aug 2025 Pg. 267-278	Legal Challenges to Compounding Drugs for Weight Loss Author(s): Combs Blinn E, Howard Brad
Mar/Apr 2018 Pg. 108-121	Personalized Medicine and Customized Drug Delivery Systems: The New Trend of Drug Delivery and Disease Management Author(s): Soni Abhishek, Gowthamarajan Kuppusamy, Radhakrishnan Arun